Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance
Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infections
(HELLERUP, DENMARK and BOSTON, US: November 18, 2026) – The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobial resistance (AMR). Building upon its initial US$25 million grant in 2024, the Novo Nordisk Foundation is now increasing its contribution with US$60 million in funding over the next four years.


